Tirzepatide 10mg ZPHC
Tirzepatid is agonistom receptors gastrointestinalP and GPP-1.
Description
Tirzepatid reduces body weight body and body weight fat in body. Mechanisms, associated with reduction mass body and zhirovoy mass include in themselves reduced intake food due to through regulation appetite. According to data from clinical studies, tirzepatid reduces intake energy and appetite due to through enhancement feelings satiety and fullness, a also blunting feelings hunger.
Specifications
• Drug class – nesteroidnyy fat burner;
• Chemical formula – C225H348N48O68;
• Administration – parenteral (injection);
• Lekarstvennoe use – reduced lishnego vesa, treatment apnoe vo sne, treatment diabeta II type;
• Half-life ≈ 5 days;
• Dosage ≈ individualno (from 2,5 mg do 15 mg/nedelya);
• Reduction synthesis testosterone – net;
• Aromatization – net;
• Gepatotoksichnost – net.
Composition / properties
Price for: 1 vial
Pack: 10mg Dopolnitelno: bacteriostatic diluent 10ml (in zakaze from 5 vials)
Active ingredient: tirzepatid (mundzharo)
Manufacturer: ZPHC
Country of origin: Kitay
Storage conditions: 2-6 C gradusov (refrigerator)
Srok godnosti: not menee 1-2 let
Product FAQ
Farmakodinamika
Tirzepatid reduces concentration glucose fasting and post-meal, reduces intake food and reduces body weight body u patients with sakharnym diabetom type 2. --- [Q] Pervaya and vtoraya phase sekretsii insulin
Tirzepatid usilivaet first and vtoruyu phase sekretsii insulin. --- [Q] Chuvstvitelnost k insulinu
Tirzepatid increases chuvstvitelnost k insulinu, which prodemonstrirovali rezultaty issledovaniya with ispolzovaniem metoda euglikemicheskogo giperinsulinemicheskogo klempa after 28 ned therapy. --- [Q] Oporozhnenie zheludka
Tirzepatid zaderzhivaet oporozhnenie zheludka. Naibolee prodolzhitelnaya retention nablyudaetsya after vvedeniya pervoy dozy, and so vremenem dannyy effekt umenshaetsya. Tirzepatid zamedlyaet vsasyvanie glucose post-meal, for those samym reducing concentration postprandialnoy glucose. --- [Q] Pochechnaya nedostatochnost.
Pochechnaya nedostatochnost not exerts effect in farmakokineticheskiy profil tirzepatida. Pokazateli farmakokineticheskikh parametrov tirzepatida after vvedeniya odnokratnoy dozy 5 mg otsenivali u patients with pochechnoy nedostatochnostyu razlichnoy stepeni tyazhesti (legkoy, average, tyazheloy, terminalnoy stadiey pochechnoy nedostatochnosti) compared with patsientami with normalnoy funktsiey pochek. Analogichnye rezultaty byli polucheny also for patients with sakharnym diabetom type 2 and pochechnoy nedostatochnostyu in osnovanii dannykh clinical studies
Reviews
Leave a review
Similar products
Similar products from this category. This is a separate block and not the same item from another warehouse.
You may also like
